





Diagnostics & Therapeutics of Atherosclerosis




Hans Bluyssen
09-12-2020

Atherosclerosis



Internal carotid artery



Coronary artery



Renal artery



Femoral artery

Fig. Atherosclerosis complications. Dr Philip Barlow Mills FCP (SA).

Atherosclerosis – vascular inflammation





Fig. Atherosclerotic plaque. Chmielewski, Piaszyk-Borychowska et al., Int Rev Immunol, 2016.




STAT-dependent signal integration in inflammation

Cytokines




TLR4 ligand



IFN-I

IFN-II



Synergistic amplification of genes involved in:

- response to stress
- inflammatory response
- defense response
- response to other organism
- immune response
- response to wounding



How to analyze the transcriptome?



WT C57BL6

Aorta enzymatic digestion

RNA-seq experiment outline



Bone marrow differentiation
with M-CSF

Bone marrow differentiation
with GM-CSF

Vascular smooth
muscle cells

Macrophages

Dendritic cells

Treatment
(3 replicates):

8h IFN γ

4h LPS

8h IFN γ + 4h LPS




RNA-seq



RNA-seq Work Flow





Illumina HiSeq





Blencowe B J et al. Genes Dev. 2009;23:1379-1386

IFNy and TLR Signal integration in SMCs: RNAseq



Commonly Up-regulated genes in response to IFN γ and LPS








Commonly Up-regulated genes in response to IFNy and LPS: top 20

Inflammatory
Gene
Expression
=
Amplified

No	Gene symbol	VSMC			BMDM			DC		
		IFNy	LPS	IFNyLPS	IFNy	LPS	IFNyLPS	IFNy	LPS	IFNyLPS
1	Cxcl9	82,2	4,0	2380,5	2401,1	18,7	3915,9	898,0	97,4	2682,0
2	F830016B08Rik	1272,1	6,4	2306,6	191,4	2,1	253,2	88,1	13,6	132,7
3	Gm4841	1087,3	9,0	1650,3	408,2	3,0	569,3	130,5	44,0	215,1
4	Nos2	1,8	90,9	933,3	464,2	60,9	5706,1	39,4	376,3	1809,3
5	BC023105	600,8	19,9	909,4	140,5	6,2	204,7	146,8	87,1	320,2
6	Gbp4	304,3	16,4	795,8	341,8	4,0	648,9	63,2	31,4	69,6
7	ligrp1	687,7	9,2	779,3	521,6	12,9	648,6	590,7	194,7	607,2
8	Ubd	95,6	5,8	655,1	65,9	1,1	124,8	214,5	1,0	258,7
9	Gbp10	315,9	21,1	588,2	200,1	17,7	364,0	33,4	33,6	48,6
10	Gbp9	304,8	22,9	586,1	25,6	1,2	31,6	8,9	13,3	10,3
11	Gbp6	266,1	23,5	555,3	181,8	17,4	332,5	32,2	35,8	49,8
12	Serpina3f	200,1	13,0	529,6	1442,5	16,9	2126,6	533,3	229,0	1133,6
13	Gbp11	302,3	13,6	482,7	149,6	6,7	243,9	40,3	24,2	44,1
14	Gm12250*	502,9	3,6	477,8	31,4	17,0	40,3	13,8	24,9	21,4
15	Gbp8	215,5	12,9	405,2	47,8	1,5	57,8	13,9	3,1	6,2
16	Ciita*	704,4	2,0	376,5	9,4	-2,6	3,6	5,4	1,3	2,5
17	Cxcl10	49,8	4,6	364,9	211,7	179,5	829,0	19,5	580,2	237,5
18	Gbp1	295,0	17,5	364,8	375,8	16,0	428,3	63,8	21,9	56,2
19	Gja4	82,3	1,6	329,9	90,1	1,0	145,3	14,8	6,9	45,9
20	Gm4951	300,1	6,9	327,2	74,9	4,5	74,4	59,5	45,3	80,5

Commonly Up-regulated genes in response to IFN γ and LPS: promoter analysis



**STAT1 & p65
mediated
Signal integration?**

Promoter region: -950 +50 bp



STAT1 ChIP-seq experiment outline







Fig. Nagy Lab modified Mandrup's ChIP protocol. Figure adapted from Nature Methods - 4: 613 – 614. 2007.


Commonly IFN γ /LPS Up-regulated genes: STAT1 & p65 binding



Binding mode	IFN γ +LPS
GAS	17
ISRE	45
NFkB	28
GAS-ISRE	53
GAS-NFkB	40
ISRE-NFkB	59
GAS-ISRE-NFkB	178




Commonly IFN γ /LPS upregulated genes: STAT1 + p65 binding





Different “Binding Modes”


STAT1-dependent epigenetic changes & nearby NF κ B binding



IFN γ /LPS mediated signal integration in CVD




Nucleus ↑



Synergistic amplification of genes involved in:

- response to stress
- inflammatory response
- defense response
- response to other organism
- immune response
- response to wounding



Crosstalk results in increased monocyte adhesion and splenocytes migration



Monocyte-EC adhesion



Hallmarks of Vascular inflammation




Splenocyte migration




Abolished response to norepinephrine in aortic rings stimulated with IFNy and LPS

Vessel Contraction
Mesenteric arteries




pSTAT1, CXCL9 and -10 in human carotid plaque SMCs






Atherosclerotic plaque transcriptomes: Data Mining



Carotid


Coronary



Carotid n=124
Coronary n=80
Controls n=80


GO terms
functions
pathways
transcription factor
binding sites


Carotid and coronary plaques share a gene signature




GO term	GO ID	p-value
cell chemotaxis	GO:0060326	2.75E-08
locomotion	GO:0040011	8.40E-08
leukocyte chemotaxis	GO:0030595	1.32E-07
chemotaxis	GO:0006935	1.45E-07
taxis	GO:0042330	1.45E-07
leukocyte migration	GO:0050900	1.80E-07
immune system process	GO:0002376	2.63E-07
cell migration	GO:0016477	4.33E-07
immune response	GO:0006955	7.70E-07
cell motility	GO:0048870	1.06E-06
cellular extravasation	GO:0045123	6.57E-05
cellular response to lipoprotein particle stimulus	GO:0071402	8.46E-05
cellular response to lipopolysaccharide	GO:0071222	1.67E-04
cellular response to interferon-gamma	GO:0071346	5.61E-03
response to interferon-gamma	GO:0034341	8.41E-03

Inflammatory genes upregulated in plaques can be regulated by STAT1







IFN γ /LPS STAT1-target genes: Biomarkers in CAD?



We identified a STAT1-dependent gene signature that reflects a pro-atherogenic state in human atherosclerosis.




STAT1, NF- κ B & IRFs in vascular disease







Inhibition of STATs & IRFs in Vascular Disease




STAT Structure & Dimerization






Structural information: STAT1-STAT3






New homology models for all STATs: STAT-SH2 small molecule interactions



High SH2 homology!

STAT inhibition approach






Novel STAT Inhibitors: Virtual Screening


HSTAT1-SH2 model

A free database for virtual screening
ZINC
zinc13.com/




Multi STAT inhibitors bind *in silico* SH2 models of STAT1, 2 and 3


C01L_03




STATTIC



STX-0119




Multi STAT inhibitors Inhibit phosphorylation of STAT1, 2 and 3




Multi-STAT inhibitors block inflammation induced gene expression


C01L_03



STATTIC




STX-0119





IFN γ /LPS C01L_F03 STATTC STX-0119

159 genes
commonly
inhibited by
C01L_F03,
STATTC,
STX-0119



Genome-wide effect of multi-STAT inhibitors

GO term	Biological Process	Fold Enrichment
GO:0043207	response to external biotic stimulus	28.14
GO:0009607	response to biotic stimulus	27.38
GO:0006952	defense response	29.61
GO:0019221	cytokine-mediated signaling pathway	29.62
GO:0002376	immune system process	28.66
GO:0001817	regulation of cytokine production	10.67
GO:0007166	cell surface receptor signaling pathway	13.89
GO:0006954	inflammatory response	8.28
GO:0042127	regulation of cell proliferation	7.97
GO:0042981	regulation of apoptotic process	4.23
GO:0030334	regulation of cell migration	4.70
GO:0030155	regulation of cell adhesion	9.09


Vascular inflammation

Multi-STAT inhibitors act in a “STAT-only” manner


ISRE




GAS



NF κ B




159 commonly
Inhibited genes




Multi-STAT inhibitors act in a "STAT-only" manner



A





B



Multi-STAT inhibitors block inflammation induced EC-migration




Multi-STAT inhibitors block inflammation induced leukocyte-EC adhesion




Multi-STAT inhibitors restore inflammation induced impaired arterial contractility

Mesenteric arteries



STATTIC (1 nM)







* - relative to Control

+ - relative to IFNγ+LPS

* - relative to Control




STAT-target gene expression in HFD treated ApoEKO mice




ApoEKO + 10 weeks HFD



Pipeline approach to identify potent STAT & IRF inhibitors



STATs & IRFs in Diagnostics & Therapeutics





Acknowledgements

UAM, IMBB

Lab HMG

Dr. Katarzyna Kluzek

Dr. Arkadiusz Kajdez

Dr. Mahdi Eskandarian
Boroujeni

Hanna Nowicka

Anna Piaszyk-Borychowska

Agata Michalska

Martyna Plens Gałaska

Aleksandra Antonczyk

Sanaz Hassani

Dr. Bart Krist



Lab of HTT

Prof J. Wesoly

Natalia Derebecka

University of Valencia

Faculty of Medicine

Prof. Maria Jesus Sanz

National Taiwan University

Dept. Immunology

Prof C-K Lee

University of Debrecen

Clinical Genomics and

Personalized Medicine

Prof. Laszlo Nagy

Dr. Balint Laszlo Balint

University of Madrid

Department of Pharmacology

School of Medicine

Prof. Concha Piero



Department of Human Molecular Genetics

Laboratory of High Throughput Technologies

<http://dhmg.amu.edu.pl>



Acknowledgements




Polish Ministry
Of Science and
Higher Education



Polish
Science
Foundation

KRAJOWY NAUKOWY
OŚRODEK WIODĄCY
POZNAŃSKIE
KONSORCJUM
RNA




- Visegrad Fund
-
-



UNIA EUROPEJSKA
EUROPEJSKI FUNDUSZ
ROZWOJU REGIONALNEGO



INNOWACYJNA
GOSPODARKA
NARODOWA STRATEGIA SPÓJNOŚCI



Department of Human Molecular Genetics
Laboratory of High Throughput Technologies

<http://dhmg.amu.edu.pl>